These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9737696)

  • 1. Biweekly THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate- and high-grade non-Hodgkins's lymphoma.
    Niitsu N; Umeda M
    Leukemia; 1998 Sep; 12(9):1457-60. PubMed ID: 9737696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non-Hodgkin's lymphoma in elderly patients: a prospective study.
    Niitsu N; Umeda M
    Leukemia; 1997 Nov; 11(11):1817-20. PubMed ID: 9369412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma.
    Niitsu N; Umeda M
    Eur J Haematol; 1996 Mar; 56(3):163-7. PubMed ID: 8598236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response and adverse drug reactions to combination chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma: comparison of CHOP, COP-BLAM, COP-BLAM III, and THP-COPBLM.
    Niitsu N; Umeda M
    Eur J Haematol; 1999 Nov; 63(5):337-44. PubMed ID: 10580566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients.
    Shpilberg O; Shiff J; Chetrit A; Ramot B; Ben-Bassat I
    Cancer; 1994 Dec; 74(11):3029-33. PubMed ID: 7525042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COP-BLAM regimen combined with granulocyte colony-stimulating factor and high-grade non-Hodgkin's lymphoma.
    Niitsu N; Umeda M
    Eur J Haematol; 1995 Aug; 55(2):88-92. PubMed ID: 7543059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
    Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
    Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Usefulness of THP-COPBLM therapy in elderly patients with non-Hodgkin's lymphoma].
    Niitsu N; Nakayama M; Umeda M
    Gan To Kagaku Ryoho; 1997 Jan; 24(1):61-6. PubMed ID: 9020947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study. The Adult Lymphoma Treatment Study Group (ALTSG).
    Niitsu N; Okamoto M; Kuraishi Y; Nakamura S; Kodama F; Hirano M
    Eur J Haematol; 2000 Sep; 65(3):188-94. PubMed ID: 11007055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pirarubicin-induced myocardial damage in elderly patients with non-Hodgkin's lymphoma].
    Niitsu N; Yamazaki J; Nakayama M; Umeda M
    Nihon Ronen Igakkai Zasshi; 1998 May; 35(5):358-62. PubMed ID: 9735010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [COP-BLAM III regimen for elderly non-Hodgkin's lymphoma].
    Niitsu N; Umeda M; Shirai T
    Nihon Ronen Igakkai Zasshi; 1993 Sep; 30(9):753-8. PubMed ID: 7693992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
    Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC
    Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
    Mori M; Kitamura K; Masuda M; Hotta T; Miyazaki T; Miura AB; Mizoguchi H; Shibata A; Saito H; Matsuda T; Masaoka T; Harada M; Niho Y; Takaku F
    Int J Hematol; 2005 Apr; 81(3):246-54. PubMed ID: 15814336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Full-dose CHOP chemotherapy combined with granulocyte colony-stimulating factor for aggressive non-Hodgkin's lymphoma in elderly patients: a prospective study.
    Niitsu N; Iijima K
    Ann Hematol; 2001 Oct; 80(10):602-6. PubMed ID: 11732872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.
    Tsurumi H; Yamada T; Sawada M; Kasahara S; Kanemura N; Kojima Y; Fukuno K; Hara T; Saio M; Takahashi T; Oyama M; Ozawa K; Takami T; Moriwaki H
    J Cancer Res Clin Oncol; 2004 Feb; 130(2):107-13. PubMed ID: 14648210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of front-line chemotherapy for aggressive non-Hodgkin's lymphoma using the CAP-BOP regimens. The Nebraska Lymphoma Study Group.
    Vose JM; Anderson JR; Bierman PJ; Bast M; Weisenburger D; Chan WC; Bishop MR; Armitage JO
    Semin Hematol; 1994 Apr; 31(2 Suppl 3):4-8. PubMed ID: 7521065
    [No Abstract]   [Full Text] [Related]  

  • 19. [Assessment of cardiac toxicity by 123I-MIBG myocardial SPECT in elderly non-Hodgkin lymphoma patients treated with COP-BLAM and G-CSF].
    Niitsu N; Umeda M
    Rinsho Ketsueki; 1995 Nov; 36(11):1326-8. PubMed ID: 8691577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
    Zagonel V; Babare R; Merola MC; Talamini R; Lazzarini R; Tirelli U; Carbone A; Monfardini S
    Ann Oncol; 1994; 5 Suppl 2():127-32. PubMed ID: 7515645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.